Dakota Wealth Management Purchases 18,256 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Dakota Wealth Management increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,549 shares of the biopharmaceutical company's stock after buying an additional 18,256 shares during the period. Dakota Wealth Management's holdings in Bristol Myers Squibb were worth $16,989,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $16,651,000. Avaii Wealth Management LLC increased its holdings in shares of Bristol Myers Squibb by 590.9% in the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock valued at $4,794,000 after purchasing an additional 67,221 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Bristol Myers Squibb by 1.4% in the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock valued at $3,967,000 after purchasing an additional 869 shares during the last quarter. Shorepoint Capital Partners LLC increased its holdings in shares of Bristol Myers Squibb by 2.2% in the fourth quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock valued at $3,305,000 after purchasing an additional 1,248 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Bristol Myers Squibb by 17.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company's stock valued at $33,582,000 after purchasing an additional 80,087 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

BMY stock traded up $0.63 during trading on Thursday, reaching $47.80. 8,170,028 shares of the company were exchanged, compared to its average volume of 12,791,670. The company has a 50-day moving average of $47.42 and a two-hundred day moving average of $53.06. The company has a market capitalization of $97.28 billion, a price-to-earnings ratio of 17.92, a P/E/G ratio of 2.39 and a beta of 0.36. Bristol Myers Squibb Company has a twelve month low of $41.20 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($4.40) EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.19%. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BMY shares. UBS Group decreased their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group reduced their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Morgan Stanley reduced their target price on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a research report on Thursday, July 10th. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.